Jasper Ridge Partners’s Mersana Therapeutics MRSN Stock Holding History

Jasper Ridge Partners’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-924	Closed	-$6.84K	–	146
2025 Q2	$6.84K	Hold	924	–	–	﹤0.01%	147
2025 Q1	$7.95K	Hold	924	–	–	﹤0.01%	147
2024 Q4	$33K	Hold	924	–	–	﹤0.01%	143
2024 Q3	$43.7K	Hold	924	–	–	﹤0.01%	142
2024 Q2	$46.4K	Hold	924	–	–	﹤0.01%	144
2024 Q1	$103K	Hold	924	–	–	﹤0.01%	140
2023 Q4	$53.6K	Hold	924	–	–	﹤0.01%	141
2023 Q3	$29.3K	Hold	924	–	–	﹤0.01%	143
2023 Q2	$76K	Hold	924	–	–	﹤0.01%	137
2023 Q1	$94.9K	Hold	924	–	–	﹤0.01%	143
2022 Q4	$135K	Hold	924	–	–	0.01%	132
2022 Q3	$156K	Hold	924	–	–	0.01%	133
2022 Q2	$107K	Hold	924	–	–	0.01%	137
2022 Q1	$92K	Hold	924	–	–	﹤0.01%	147
2021 Q4	$144K	Hold	924	–	–	0.01%	147
2021 Q3	$218K	Hold	924	–	–	0.01%	138
2021 Q2	$314K	Hold	924	–	–	0.02%	118
2021 Q1	$374K	Sell	924 -121	-12%	-$58.7K	0.02%	105
2020 Q4	$695K	Buy	1,045 +581	+125%	+$323K	0.03%	89
2020 Q3	$216K	Buy	+464	New	+$234K	0.01%	107

Other funds holding MRSN

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jasper Ridge Partners's MRSN Position: Q3 2025 in Review

Jasper Ridge Partners sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 924 shares — an estimated $6.84K sold.

Jasper Ridge Partners first reported a position in MRSN in Q3 2020 and held it in 20 quarters. The position peaked at $695K in Q4 2020. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

Jasper Ridge Partners reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
Jasper Ridge Partners sold 924 Mersana Therapeutics shares in Q3 2025, an estimated $6.84K.
Jasper Ridge Partners first reported a position in Mersana Therapeutics in Q3 2020 and held it in 20 quarters.
Jasper Ridge Partners's Mersana Therapeutics position peaked at $695K in Q4 2020.
49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Jasper Ridge Partners's 13F filing for Q3 2025, filed 17 Nov 2025.